Drug Trial Radar · NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
680
Planned (sponsor's estimate)
Start
Apr 10, 2024
Primary completion
Jul 25, 2028
Study completion Jul 25, 2028
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Mar 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; cutaneous melanoma; and neuroendocrine carcinoma (NEC).
Conditions
- Recurrent or Metastatic Solid Tumors
Interventions
Ifinatamab deruxtecanDrug
Intravenous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) as Assessed by InvestigatorTime frame: From the time of the first dose of study drug until the date of documented disease progression, death, loss to follow-up, or withdrawal by the subject, whichever occurs first (up to approximately 60 months)
- Number of Participants Reporting Dose-limiting Toxicities (DLTs) in the HCC CohortTime frame: Cycle 1 Day 1 to Cycle 1 Day 21
- Number of Participants Reporting TEAEs and Death in the HCC CohortTime frame: From date of signing the informed consent form up to 47 days after the last dose of study drug, up to approximately 60 months
Locations
120 sites in 18 countries. Site status is shown where the registry gives one.
Valkyrie Clinical Trials
Los Angeles, California · Active not recruiting
Los Angeles Cancer Network
Los Angeles, California · Recruiting
Pih Health Hematology Medical Oncology
Whittier, California · Recruiting
Orchard Healthcare Research Inc
Skokie, Illinois · Recruiting
M Health Fairview University of Minnesota Medical Center
Minneapolis, Minnesota · Recruiting
NYU Langone Health
New York, New York · Recruiting
Icahn School of Medicine At Mount Sinai Prime
New York, New York · Recruiting
Clinical Research Alliance, Inc
Westbury, New York · Recruiting
White Plains Hospital
White Plains, New York · Recruiting
Erlanger Health, Inc
Chattanooga, Tennessee · Recruiting
The West Clinic
Germantown, Tennessee · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Texas Oncology - West Texas
Amarillo, Texas · Recruiting
Texas Oncology, P.A.
Dallas, Texas · Recruiting
Texas Oncology Gulf Coast
Pearland, Texas · Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Wenatchee Valley Hospital and Clinics
Wenatchee, Washington · Recruiting
DIABAID
Buenos Aires, Argentina · Not yet recruiting
Centro Médico Austral
Ciudad Autonoma Buenos Aires, Argentina · Active not recruiting
Centro de Investigaciones Medicas y Desarrollo LC SRL LC Investigacion
Ciudad Autonoma Buenos Aires, Argentina · Recruiting
Centro de Investigaciones Medicas Mar Del Plata
Mar del Plata, Buenos Aires, Argentina · Recruiting
Hospital Aleman
Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina · Recruiting
Hospital Sirio Libanes
Caba, Ciudad Autonoma Buenos Aires, Argentina · Recruiting
Blacktown Hospital
Blacktown, New South Wales, Australia · Recruiting
St Vincent'S Hospital Sydney
Mount Kuring-Gai, New South Wales, Australia · Recruiting
Genesiscare North Shore Oncology
St Leonards, New South Wales, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
St John of God Subiaco Hospital
Subiaco, Western Australia, Australia · Recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Recruiting
Grand Hospital de Charleroi
Charleroi, Belgium · Recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Not yet recruiting
Uz Leuven
Leuven, Belgium · Recruiting
Chu de Liă Ge
Liège, Belgium · Not yet recruiting
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Hospital São Lucas Da Pucrs
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Cepon - Centro de Pesquisas Oncolă"Gicas de Santa Catarina
Florianópolis, Santa Catarina, Brazil · Recruiting
Hospital de Câncer de Barretos - Fundação Pio XII
Barretos, São Paulo, Brazil · Recruiting
Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho
Jaú, São Paulo, Brazil · Recruiting
Ic La Serena Research
La Serena, Chile · Not yet recruiting
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.